Wolverine Trading’s Crescent Biopharma CBIO Stock Holding History

Wolverine Trading’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-150	Closed	-$19K	–	4495
2023 Q1	$19K	Buy	+150	New	+$33.8K	﹤0.01%	4016

Other funds holding CBIO

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wolverine Trading's CBIO Position: Q2 2023 in Review

Wolverine Trading sold out of Crescent Biopharma (CBIO) in Q2 2023, closing a stake of 119 shares — an estimated $15K sold.

Wolverine Trading first reported a position in CBIO in Q1 2023 and held it in 1 quarter. The position peaked at $15K in Q1 2023. 55 funds tracked by Wall St. Rank hold CBIO as of Q2 2023.

Wolverine Trading reported no remaining Crescent Biopharma position as of Q2 2023 after selling out during the quarter.
Wolverine Trading sold 119 Crescent Biopharma shares in Q2 2023, an estimated $15K.
Wolverine Trading first reported a position in Crescent Biopharma in Q1 2023 and held it in 1 quarter.
Wolverine Trading's Crescent Biopharma position peaked at $15K in Q1 2023.
55 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2023.

Based on Wolverine Trading's 13F filing for Q2 2023, filed 23 Aug 2023.